Researchers at National Institutes of Health highlighted that Colchicine, a drug generally used in the treatment of arthritic condition gout, might potentially minimize complications associated with metabolic syndrome. This syndrome is said to be a mixture of high blood sugar, high blood pressure, and other conditions leading to boost the threat of type 2 diabetes and heart disease. The latest study can be accessed in the journal Diabetes, Endocrinology, and Metabolism.
Earlier studies have pointed out that the system-wide inflammation occurring in obesity plays a part in type 2 diabetes development. The latest research was headed by Jack A. Yanovski, M.D., Ph.D., Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), NIH. In the present study, randomly assigned 21 research participants were offered colchicine twice per day for about 3 Months period. At the same time, the other 19 participants were receiving a placebo. Colchicine is found to suppress a multi-protein complex named NLRP3, which activates the inflammation observed in obesity.
On a similar note, researchers from Karolinska Institutet came into the news as they disclosed a method that can explain the impaired injury healing in diabetes which can cause diabetic foot ulcers. The research is published in the journal PNAS. In the latest research carried out, the diabetic mice wound healing was advanced when the known signaling pathway was obstructed.
Diabetic foot ulcerations are said to be a widespread complication in diabetes. It constitutes a huge social, medical, and economic problem today. The lifetime threat of an individual with type 1 or type 2 diabetes to develop a foot ulcer is approximately 15%. The treatment choices are presently limited owing to a poor understanding of the pathogenic systems. Now scientists from Karolinska Institutet have discovered a signaling pathway between cells, which is known for playing a key part in the impaired wound healing in diabetes.